Recruiting

STIMIT Activator 1

Sponsor:

Stimit AG

Code:

NCT05883163

Conditions

Diaphragm Issues

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Stimit Activator 1

Study Details

Brief summary:

The study is a prospective, multi-center, randomized, controlled study using adaptive design to assess the evidence of safety and performance of the STIMIT Activator 1 System in the treatment of patients who have been mechanically ventilated for up to 7 days and are predicted to require additional minimum 48 hours of mechanical ventilation or longer.

Conditions

Diaphragm Issues

Study ID

NCT05883163

Start date

Jan 24, 2024

Status verified date

Nov, 2025

Completion date

Jul, 2026

Anticipated

Primary completion date

Apr, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Are 21 years or older, and,
2. Have recently been placed on invasive MV (enroll and randomized as soon as possible after intubation), and have received no more than 7 days of MV
3. Are predicted to remain on mechanical ventilation for an additional 48 hours or longer post randomization

Exclusion Criteria:

1. Patients that are actively treated with continuous infusion of neuromuscular blocking agents beyond the enrollment period.
2. Medical condition known to affect the phrenic nerve or respiratory muscles (examples of possible medical conditions that could affect the phrenic nerve provided in Annex 1 below).
3. Any patients with ICP probe.
4. Patients with metallic device implants or body penetrating metallic devices in the upper body area within 30cm (12inches) from the coils; known anatomy or devices in the neck area (e.g., ECMO cannulas in the neck area, collars or cranial appliances) that would interfere with headset placement or stimulation.
5. Any non-removable electrical / electronic device (device internal or external) that may be prone to interaction with, or interference from the STIMIT Activator, such as pacemakers, implantable defibrillators, implanted medication pumps, bio-stimulators, deep brain stimulators, implanted nerve stimulator, deep brain stimulators or cochlear device implants.
6. BMI >40.
7. Cardiogenic or septic shock with ongoing severe hemodynamic instability that cannot be stabilized within the enrollment period.
8. Physician thinks that the patient will not tolerate initial installation of the STIMIT respiratory sensor.
9. Anticipating withdrawal of life support and/or shift to palliation as the goal of care.
10. Known to be pregnant.
11. Participating in another clinical trial studying an experimental Intervention that could affect the study primary outcome.
12. Patients whose ultrasonographic assessment of right-sided diaphragmatic thickness would be too difficult (e.g. local subcutaneous emphysema surrounding the zone of apposition, large dressings in the zone of apposition that cannot be removed).
13. Patients with neck condition that would not allow placing the coils on the neck (e.g. open wounds that cannot be covered, skin at risk for burns).
14. Patients with significant spontaneous efforts (P0.1 < - 2) that would not be at risk for diaphragmatic atrophy/ dysfunction.

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Stimulation Group

The intervention group will receive non-invasive stimulation of the phrenic nerve for activation of the diaphragm.

no intervention: Control Group

The control group will not received intervention and will be treated with standard of care.

Interventions

Stimit Activator 1

The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.

Primary outcome measure

  • Efffectiveness: Preservation of Diaphragm Thickness [ Time Frame: Up to Day 10 ]
  • Safety: Rate of device or procedure related serious adverse events (SAEs) [ Time Frame: Up to Day 10 ]

Central Contacts and Locations

Central contacts

Locations

Yale New Haven Hospital

Recruiting

New Haven, Connecticut, United States, 06510

Contacts

Rodolfo Nelson Molina

Rodolfo.molina@yale.edu

Principal Investigator:

Pramod Bonde, MD, FACS

Beth Israel Deaconess Medical Center

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Principal Investigator:

Elias Baedorf Kassis, MD

University of Virginia Medical Center

Recruiting

Charlottesville, Virginia, United States, 22908

Contacts

Principal Investigator:

Danny J. Theodore, MD

St Michael's Hospital Unity Health Toronto

Recruiting

Toronto, Canada

Contacts

Marlene Santos-Taylor

Marlene.Santos@unityhealth.to

Principal Investigator:

Laurent Brochard, MD

More Information

Sponsor

Stimit AG

Last update posted

Nov 14, 2025

Last verified

Nov, 2025

Keywords

  • Non-Invasive Phrenic Nerve Stimulation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Stimit AG on 2025-11-14.